Annual CFO
-$56.78 M
-$17.66 M-45.13%
December 31, 2023
Summary
- As of February 8, 2025, AVTE annual cash flow from operations is -$56.78 million, with the most recent change of -$17.66 million (-45.13%) on December 31, 2023.
- During the last 3 years, AVTE annual CFO has fallen by -$48.92 million (-622.46%).
- AVTE annual CFO is now -1941.64% below its all-time high of -$2.78 million, reached on December 31, 2019.
Performance
AVTE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$16.04 M
+$4.39 M+21.48%
September 30, 2024
Summary
- As of February 8, 2025, AVTE quarterly cash flow from operations is -$16.04 million, with the most recent change of +$4.39 million (+21.48%) on September 30, 2024.
- Over the past year, AVTE quarterly CFO has dropped by -$1.24 million (-8.40%).
- AVTE quarterly CFO is now -1256.13% below its all-time high of -$1.18 million, reached on March 1, 2020.
Performance
AVTE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$74.95 M
-$432.00 K-0.58%
September 30, 2024
Summary
- As of February 8, 2025, AVTE TTM cash flow from operations is -$74.95 million, with the most recent change of -$432.00 thousand (-0.58%) on September 30, 2024.
- Over the past year, AVTE TTM CFO has dropped by -$18.17 million (-32.00%).
- AVTE TTM CFO is now -6235.50% below its all-time high of -$1.18 million, reached on March 1, 2020.
Performance
AVTE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AVTE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -45.1% | -8.4% | -32.0% |
| 3 y3 years | -622.5% | -8.4% | -32.0% |
| 5 y5 years | -1941.6% | -8.4% | -32.0% |
AVTE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -107.2% | at low | -183.4% | +32.2% | -173.6% | at low |
| 5 y | 5-year | -1941.6% | at low | -1256.1% | +32.2% | -6235.5% | at low |
| alltime | all time | -1941.6% | at low | -1256.1% | +32.2% | -6235.5% | at low |
Aerovate Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.04 M(-21.5%) | -$74.95 M(+0.6%) |
| Jun 2024 | - | -$20.43 M(-13.7%) | -$74.52 M(+8.0%) |
| Mar 2024 | - | -$23.67 M(+60.0%) | -$69.03 M(+21.6%) |
| Dec 2023 | -$56.78 M(+45.1%) | -$14.80 M(-5.2%) | -$56.78 M(-0.1%) |
| Sep 2023 | - | -$15.61 M(+4.5%) | -$56.84 M(+11.6%) |
| Jun 2023 | - | -$14.94 M(+30.8%) | -$50.95 M(+13.5%) |
| Mar 2023 | - | -$11.42 M(-23.1%) | -$44.88 M(+14.7%) |
| Dec 2022 | -$39.12 M | -$14.87 M(+52.9%) | -$39.12 M(+4.7%) |
| Sep 2022 | - | -$9.72 M(+9.5%) | -$37.35 M(+9.4%) |
| Jun 2022 | - | -$8.88 M(+56.8%) | -$34.16 M(+16.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$5.66 M(-56.8%) | -$29.29 M(+6.9%) |
| Dec 2021 | -$27.40 M(+248.6%) | -$13.09 M(+100.6%) | -$27.40 M(+59.4%) |
| Sep 2021 | - | -$6.53 M(+62.9%) | -$17.19 M(+31.3%) |
| Jun 2021 | - | -$4.00 M(+6.1%) | -$13.10 M(+25.3%) |
| Mar 2021 | - | -$3.77 M(+30.9%) | -$10.45 M(+33.0%) |
| Dec 2020 | -$7.86 M(+182.6%) | -$2.88 M(+18.5%) | -$7.86 M(+58.0%) |
| Sep 2020 | - | -$2.43 M(+79.0%) | -$4.97 M(+95.7%) |
| Jun 2020 | - | -$1.36 M(+14.9%) | -$2.54 M(+114.9%) |
| Mar 2020 | - | -$1.18 M | -$1.18 M |
| Dec 2019 | -$2.78 M | - | - |
FAQ
- What is Aerovate Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual CFO year-on-year change?
- What is Aerovate Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly CFO year-on-year change?
- What is Aerovate Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aerovate Therapeutics?
- What is Aerovate Therapeutics TTM CFO year-on-year change?
What is Aerovate Therapeutics annual cash flow from operations?
The current annual CFO of AVTE is -$56.78 M
What is the all time high annual CFO for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual cash flow from operations is -$2.78 M
What is Aerovate Therapeutics annual CFO year-on-year change?
Over the past year, AVTE annual cash flow from operations has changed by -$17.66 M (-45.13%)
What is Aerovate Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AVTE is -$16.04 M
What is the all time high quarterly CFO for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly cash flow from operations is -$1.18 M
What is Aerovate Therapeutics quarterly CFO year-on-year change?
Over the past year, AVTE quarterly cash flow from operations has changed by -$1.24 M (-8.40%)
What is Aerovate Therapeutics TTM cash flow from operations?
The current TTM CFO of AVTE is -$74.95 M
What is the all time high TTM CFO for Aerovate Therapeutics?
Aerovate Therapeutics all-time high TTM cash flow from operations is -$1.18 M
What is Aerovate Therapeutics TTM CFO year-on-year change?
Over the past year, AVTE TTM cash flow from operations has changed by -$18.17 M (-32.00%)